"PROTINUS" (lat. forward, further") is the name of the project with which the biopharmaceutical company CSL Behring will significantly increase the production capacity of immunoglobulin at its site.

Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...

CSL Behring has been honored with this prestigious award recognizing innovation and excellence in pharmaceutical facility projects, as the FOYA program celebrates its 20 th anniversary "As FOYA marks ...

With an AstraZeneca vaccine deal confirmed and negotiations ongoing with other shot-makers, the Australian government is looking to domestic manufacturer CSL Behring to churn out supplies. CSL has ...